Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 11/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739346 | 0.88 | NR1I3 (0.43) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14740360 | 0.85 | NR1I3 (0.43) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14740266 | 0.78 | DPP4 (0.42) | NR1I3NR1I2DPP4KDM4EHSD17B10 | |
| SCHEMBL14740335 | 0.78 | LMNA (0.46) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14740051 | 0.78 | NR1I3 (0.43) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14740209 | 0.77 | DPP4 (0.43) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14739347 | 0.77 | KMT2A (0.53) | NR1I3DPP4KDM4EKMT2A | |
| SCHEMBL14739267 | 0.77 | DPP4 (0.42) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14740387 | 0.76 | DPP4 (0.42) | NR1I3NR1I2DPP4KDM4EKMT2A | |
| SCHEMBL14739888 | 0.73 | NR1I3 (0.40) | NR1I3NR1I2DPP4KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | claimed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | claimed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | NR1I3 197/4885NR1I2 147/4885DPP4 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.